DK1524266T3 - Farmaceutisk sammensætning - Google Patents

Farmaceutisk sammensætning

Info

Publication number
DK1524266T3
DK1524266T3 DK04077714T DK04077714T DK1524266T3 DK 1524266 T3 DK1524266 T3 DK 1524266T3 DK 04077714 T DK04077714 T DK 04077714T DK 04077714 T DK04077714 T DK 04077714T DK 1524266 T3 DK1524266 T3 DK 1524266T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
DK04077714T
Other languages
Danish (da)
English (en)
Inventor
Giuseppe Alvaro
Fabio Romano Di
Paolo Maragni
Marisa Tampieri
Maria Elvira Tranquillini
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1524266T3 publication Critical patent/DK1524266T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
DK04077714T 2000-10-17 2001-10-12 Farmaceutisk sammensætning DK1524266T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0025354.2A GB0025354D0 (en) 2000-10-17 2000-10-17 Chemical compounds
PCT/GB2001/004580 WO2002032867A1 (en) 2000-10-17 2001-10-12 Chemical compounds

Publications (1)

Publication Number Publication Date
DK1524266T3 true DK1524266T3 (da) 2007-06-25

Family

ID=9901397

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01976453T DK1326832T3 (da) 2000-10-17 2001-10-12 Kemiske forbindelser
DK04077714T DK1524266T3 (da) 2000-10-17 2001-10-12 Farmaceutisk sammensætning

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK01976453T DK1326832T3 (da) 2000-10-17 2001-10-12 Kemiske forbindelser

Country Status (29)

Country Link
US (5) US7119092B2 (US07648990-20100119-C00004.png)
EP (4) EP1524266B1 (US07648990-20100119-C00004.png)
JP (1) JP3940359B2 (US07648990-20100119-C00004.png)
KR (1) KR100847414B1 (US07648990-20100119-C00004.png)
CN (1) CN1231468C (US07648990-20100119-C00004.png)
AR (1) AR034268A1 (US07648990-20100119-C00004.png)
AT (3) ATE355271T1 (US07648990-20100119-C00004.png)
AU (4) AU9572301A (US07648990-20100119-C00004.png)
BR (1) BR0114637A (US07648990-20100119-C00004.png)
CA (1) CA2425876C (US07648990-20100119-C00004.png)
CY (1) CY1107634T1 (US07648990-20100119-C00004.png)
CZ (1) CZ299824B6 (US07648990-20100119-C00004.png)
DE (3) DE60106287T2 (US07648990-20100119-C00004.png)
DK (2) DK1326832T3 (US07648990-20100119-C00004.png)
ES (3) ES2227287T3 (US07648990-20100119-C00004.png)
GB (1) GB0025354D0 (US07648990-20100119-C00004.png)
HK (2) HK1058788A1 (US07648990-20100119-C00004.png)
HU (1) HU228146B1 (US07648990-20100119-C00004.png)
IL (3) IL155165A0 (US07648990-20100119-C00004.png)
MX (1) MXPA03003536A (US07648990-20100119-C00004.png)
MY (1) MY124957A (US07648990-20100119-C00004.png)
NO (1) NO324468B1 (US07648990-20100119-C00004.png)
NZ (1) NZ525091A (US07648990-20100119-C00004.png)
PL (1) PL203071B1 (US07648990-20100119-C00004.png)
PT (2) PT1326832E (US07648990-20100119-C00004.png)
SI (2) SI1326832T1 (US07648990-20100119-C00004.png)
TW (1) TWI299730B (US07648990-20100119-C00004.png)
WO (1) WO2002032867A1 (US07648990-20100119-C00004.png)
ZA (1) ZA200302801B (US07648990-20100119-C00004.png)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0108595D0 (en) 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US7482365B2 (en) 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TWI283241B (en) * 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
JP4079727B2 (ja) * 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
ATE400568T1 (de) * 2002-12-23 2008-07-15 Janssen Pharmaceutica Nv Substituierte 4-(4-piperidin-yl-piperazin-1-yl)- azepan-derivate und ihre verwendung als tachykinin-antagonisten
JO2485B1 (en) * 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
JO2696B1 (en) * 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
US7435736B2 (en) 2002-12-23 2008-10-14 Janssen Pharmaceutica, N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
JP2006516581A (ja) * 2003-01-27 2006-07-06 グラクソ　グループ　リミテッド 機能性消化不良を治療するための化学化合物の使用
FR2853648B1 (fr) * 2003-04-11 2006-08-18 Fournier Lab Sa Nouveaux derives de benzenesulfonamides et leur utilisation en therapeutique
WO2004087654A2 (en) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Phospholipase c inhibitors for use in treating inflammatory disorders
US20040235855A1 (en) * 2003-03-31 2004-11-25 Bharat Lagu Phospholipase C inhibitors for use in treating inflammatory disorders
US20040242639A1 (en) * 2003-03-31 2004-12-02 Bharat Lagu Phospholipase C inhibitors for use in treating inflammatory disorders
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
DE602004013772D1 (de) * 2003-06-10 2008-06-26 Janssen Pharmaceutica Nv Kombination von opioiden und einem piperazin-derivat für die behandlung von schmerzen
MXPA05013770A (es) * 2003-06-19 2006-03-08 Pfizer Prod Inc Antagonista de neuroquinina 1.
JO2525B1 (en) * 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
WO2006062110A1 (ja) * 2004-12-06 2006-06-15 Banyu Pharmaceutical Co., Ltd. ピペラジン誘導体
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
DE602006016244D1 (de) 2005-03-08 2010-09-30 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin-(nk1)-antagonisten
GB0514705D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds
GB0514707D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds
GB0514704D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds
JP4904945B2 (ja) 2006-06-30 2012-03-28 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体の製造方法
MX2009007916A (es) 2007-01-24 2009-07-31 Glaxo Group Ltd Composiciones farmaceuticas que comprenden 3,5-diamino-6-(2,3-dicl orofenil)-l,2,4,-triazina; o r(-)-2,4-diamino-5-(2,3-diclorofenil) -6-fluorometil pirimidina y un receptor neuroquinina 1.
AU2008299921B2 (en) 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
GB0812849D0 (en) * 2008-07-14 2008-08-20 Glaxo Wellcome Mfg Pte Ltd Novel compounds
US9782397B2 (en) 2011-07-04 2017-10-10 Irbm Science Park S.P.A. Treatment of corneal neovascularization
WO2013124286A1 (en) 2012-02-22 2013-08-29 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds
WO2015024203A1 (en) * 2013-08-20 2015-02-26 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds ii
US11160809B2 (en) 2017-04-10 2021-11-02 Chase Therapeutics Corporation NK1-antagonist combination and method for treating synucleinopathies
CN111032158A (zh) 2017-06-30 2020-04-17 才思治疗公司 用于治疗抑郁的nk-1拮抗剂组合物和方法
CN111116514B (zh) * 2020-01-10 2024-03-19 广州科锐特生物科技有限公司 一种1-环丙甲酰基哌嗪盐酸盐的制备方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US536020A (en) * 1894-04-09 1895-03-19 Washing or bathing apparatus
US4379152A (en) 1974-05-09 1983-04-05 Toyama Chemical Co., Ltd. Cephalosporins
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
US4410522A (en) 1974-05-09 1983-10-18 Toyama Chemical Co., Ltd. Cephalosporins
US4110327A (en) 1974-05-09 1978-08-29 Toyama Chemical Co., Ltd. 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4087424A (en) 1974-05-09 1978-05-02 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4327097A (en) 1974-05-09 1982-04-27 Toyama Chemical Co., Ltd. Novel penicillins
US4112090A (en) 1974-05-09 1978-09-05 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4219554A (en) 1974-05-09 1980-08-26 Toyama Chemical Company, Limited Novel penicillins and cephalosporins and process for producing same
NO154582C (no) 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
JPS57118587A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel penicillin
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
GB8709666D0 (en) 1987-04-23 1987-05-28 Beecham Group Plc Compounds
GB8713061D0 (en) 1987-06-04 1987-07-08 Beecham Group Plc Compounds
US5109014A (en) 1990-12-10 1992-04-28 Jacobson Richard M N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
ATE195867T1 (de) 1991-09-20 2000-09-15 Glaxo Group Ltd Neue medizinische indikation für tachykinin- antagonisten
EP0545478A1 (en) 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
US5334387A (en) * 1993-02-23 1994-08-02 Colgate-Palmolive Company Topical composition comprising mono and dialkyl phosphates with a cosurfactant
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
EP0655422B1 (de) 1993-11-26 1998-08-12 Deutsche Rockwool Mineralwoll-GmbH Verfahren zum Herstellen einer Schmelze für die Mineralfaserherstellung
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
TW397831B (en) 1994-07-15 2000-07-11 Meiji Seika Kaisha The anti-platelet-agglutination hexahydrogenated pyridine and its derivatives
WO1996003378A1 (fr) 1994-07-26 1996-02-08 Sankyo Company, Limited Derives d'amide n-phenyle et d'uree
DE19520499C2 (de) 1994-09-17 2003-06-18 Boehringer Ingelheim Kg Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung
US5696123A (en) 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists
US5935951A (en) 1994-09-30 1999-08-10 Novartis Finance Corporation 1-acyl-4-aliphatylaminopiperidine compounds
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
US5998444A (en) 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
AU4432496A (en) 1994-12-23 1996-07-19 Dr. Karl Thomae Gmbh Piperazine derivatives, medicaments containing the same, their use and process for preparing the same
US5700801A (en) 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
DE19608665A1 (de) 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6057323A (en) 1996-03-08 2000-05-02 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
AU706495B2 (en) 1996-04-03 1999-06-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891349A4 (en) 1996-04-03 2001-01-24 Merck & Co Inc FARNESYL-PROTEIN TRANSFERASE INHIBITORS
AU707139B2 (en) 1996-04-03 1999-07-01 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929077A (en) 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
JP2001504852A (ja) 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 双極性障害の治療のためのｎｋ−１受容体拮抗薬の使用
US6114315A (en) 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
US5977104A (en) 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
EP1014984A1 (en) 1997-08-27 2000-07-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CA2309341A1 (en) 1997-11-24 1999-06-03 Merck & Co., Inc. Substituted .beta.-alanine derivatives as cell adhesion inhibitors
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
US6253732B1 (en) * 1999-11-11 2001-07-03 Ford Global Technologies, Inc. Electronic throttle return mechanism with a two-spring and two-lever default mechanism
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

Also Published As

Publication number Publication date
ATE468324T1 (de) 2010-06-15
US20060142302A1 (en) 2006-06-29
CY1107634T1 (el) 2013-04-18
US7119092B2 (en) 2006-10-10
AU2005204234B2 (en) 2009-05-07
IL155165A (en) 2008-11-26
WO2002032867A1 (en) 2002-04-25
US20050137208A1 (en) 2005-06-23
CN1231468C (zh) 2005-12-14
EP1326832A1 (en) 2003-07-16
KR100847414B1 (ko) 2008-07-18
JP3940359B2 (ja) 2007-07-04
ES2282794T3 (es) 2007-10-16
TWI299730B (en) 2008-08-11
ATE355271T1 (de) 2006-03-15
DE60142197D1 (de) 2010-07-01
AU2009201407B2 (en) 2011-12-15
DE60106287D1 (de) 2004-11-11
HK1075889A1 (en) 2005-12-30
DE60106287T2 (de) 2006-02-23
SI1524266T1 (sl) 2007-08-31
NZ525091A (en) 2005-04-29
CA2425876C (en) 2009-07-07
IL155165A0 (en) 2003-10-31
US7060702B2 (en) 2006-06-13
KR20030036932A (ko) 2003-05-09
EP1524266A1 (en) 2005-04-20
NO324468B1 (no) 2007-10-22
ES2346108T3 (es) 2010-10-08
CZ299824B6 (cs) 2008-12-03
AU2005204234A1 (en) 2005-09-15
NO20031561D0 (no) 2003-04-07
US20080021041A1 (en) 2008-01-24
SI1326832T1 (en) 2005-02-28
DE60127002T2 (de) 2007-10-31
MXPA03003536A (es) 2003-08-07
DE60127002D1 (de) 2007-04-12
US7294630B2 (en) 2007-11-13
EP1752449A1 (en) 2007-02-14
EP1921064B1 (en) 2010-05-19
BR0114637A (pt) 2003-09-30
HUP0301459A3 (en) 2007-11-28
CA2425876A1 (en) 2002-04-25
DK1326832T3 (da) 2005-01-31
PL203071B1 (pl) 2009-08-31
AR034268A1 (es) 2004-02-18
US20040014770A1 (en) 2004-01-22
JP2004511544A (ja) 2004-04-15
NO20031561L (no) 2003-06-14
GB0025354D0 (en) 2000-11-29
EP1921064A1 (en) 2008-05-14
PT1524266E (pt) 2007-05-31
EP1524266B1 (en) 2007-02-28
AU2001295723B2 (en) 2005-05-26
ES2227287T3 (es) 2005-04-01
CZ20031082A3 (cs) 2004-08-18
HUP0301459A2 (en) 2006-09-28
HK1058788A1 (en) 2004-06-04
AU2009201407A1 (en) 2009-05-07
PL361180A1 (en) 2004-09-20
EP1326832B1 (en) 2004-10-06
MY124957A (en) 2006-07-31
US20100081667A1 (en) 2010-04-01
ZA200302801B (en) 2004-04-21
AU9572301A (en) 2002-04-29
IL191486A0 (en) 2008-11-03
PT1326832E (pt) 2005-01-31
HU228146B1 (en) 2012-12-28
CN1483025A (zh) 2004-03-17
US7648990B2 (en) 2010-01-19
ATE278669T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
DK1524266T3 (da) Farmaceutisk sammensætning
FI20105657A (fi) Farmaseuttisia koostumuksia
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
ITMI20010748A0 (it) Composizioni farmaceutiche
NO20025450L (no) Ny farmasöytisk sammensetning
NO20015175L (no) Farmasöytisk sammensetning
FI20011478A0 (fi) Farmaseuttinen koostumus
ITTO20010008A0 (it) Formulazione farmaceutica
FI991485A (fi) Uusi farmaseuttinen koostumus
PT1242087E (pt) Composicoes farmaceuticas
IS6686A (is) Hýdrógel-drifið lyfjaskömmtunarform
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
EE05020B1 (et) Glburiidi ravimkoostis
IS7051A (is) Lyfjasamsetningar
NO20026123L (no) Farmasöytiske sammensetninger
FI20022128A0 (fi) Farmaseuttinen koostumus
PT1239832E (pt) Composicoes farmaceuticas
NO20031095D0 (no) Farmasöytiske sammensetninger
DE60116858D1 (de) Zusammensetzung
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ITMI20011637A0 (it) Composizione farmaceutica contenente citalopram
FI4488U1 (fi) Farmaseuttinen koostumus
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DE60107312D1 (de) Feste Zusammensetzung
EE200200689A (et) Ravimkoostised